Table 1 Baseline characteristics according to Galectin 3 plasma concentration above or below median (median = 16.90 ng/mL). Linear variables presented: median (25–75 % percentiles)
Variable | Below median Galectin 3 (n = 64) | Above median Galectin 3 (n = 68) | P-value |
|---|---|---|---|
Age, years | 68 (62–73) | 73 (68–78) | 0.010 |
Female sex, % | 21.9 | 30.9 | 0.241 |
BMI, kg/m2 | 26 (24–29) | 27 (23–31) | 0.191 |
NYHA class III-IV, % | 15.6 | 44.1 | <0.001 |
Systolic BP, mmHg | 130 (113–143) | 122 (110–137) | 0.225 |
Diastolic BP, mmHg | 77 (70–84) | 73 (68–81) | 0.174 |
Heart rate, beats/min | 67 (59–75) | 68 (60–78) | 0.292 |
HF duration, months | 7.5 (6–12) | 12 (6–24) | 0.257 |
Medical history: | |||
Pervious MI, % | 46.9 | 32.4 | 0.088 |
Hypertension, % | 57.8 | 64.7 | 0.405 |
Atrial fibrillation, % | 35.9 | 32.4 | 0.664 |
ICD, % | 10.9 | 13.4 | 0.663 |
Diabetes, % | 18.8 | 26.5 | 0.290 |
Apoplexia Cerebri/ TCI, % | 12.5 | 22.1 | 0.148 |
Medication: | |||
ACE-I, % | 64.1 | 72.1 | 0.333 |
ARB, % | 31.7 | 22.1 | 0.211 |
Beta-blocker, % | 85.9 | 85.3 | 0.916 |
MRA, % | 12.5 | 26.9 | 0.039 |
Blood sample analysis: | |||
Hemoglobin, mmol/L | 8.9 (8.3–9.4) | 8.2 (7.6–8.8) | 0.004 |
Creatinine, umol/L | 76.0 (66.0–84.0) | 98.0 (81.0–130.5) | 0.001 |
eGFR, mL/min/1.73 m2 | 81.0 (70.0–88.0) | 55.0 (40.5–70.0) | <0.001 |
Galectin 3, ng/mL | 13.90 (12.43–14.49) | 21.85 (18.65–27.58) | <0.001 |
NTproBNP, pg/mL | 920.15 (393.75–1712.30) | 1931.15 (736.20–4059.25) | <0.001 |
ProANP, pmol/L | 726.89 (470.29–1099.33) | 1205 (658.80–1627.44) | 0.006 |
Troponin I, % above median | 32,8 | 38,2 | 0.519 |
hsCRP, mg/L | 1.64 (0.87–3.30) | 3.64 (1.61–8.21) | 0.001 |
Chromogranin A, pmol/L | 79.0 (49.0–116.0) | 106.5 (72.0–240.0) | 0.001 |
Copeptin, pmol/L | 7.89 (5.07–12.62) | 10.88 (7.03–32.85) | <0.001 |
Urine Sample analysis: | |||
Albuminuria, mg/24 h | 11.0 (9.0–23.5) | 14.0 (8.0–29.5) | 0.213 |